Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Adopts Definiens Biomarker Analysis Platform

NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

"VeriTrova accelerates clinical trials through remote uploading and viewing of digitized [immunohistochemistry] images from wet-lab partners and CROs to the cloud, where the images are analyzed," Thomas Colarusso, vice president of business development and strategy at Definiens, said in a statement.

Andrew Dorner, Takeda's vice president and global head of translational medicine, added that Definiens' system "will improve the timelines and quality of our image analysis for clinical biomarkers." 

Definiens said the real-time analysis provided by VeriTrova can help Takeda reduce normal processes from months to weeks, and can provide more automated and standardized image analysis readouts. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.